Literature DB >> 2066180

Can the HLA phenotype be used as a prognostic factor in breast carcinomas?

A Concha1, T Cabrera, F Ruiz-Cabello, F Garrido.   

Abstract

There is evidence indicating that change in the expression of HLA-ABC antigens can modulate the biological behavior and metastatic potential of certain neoplasms. We studied 15 samples of normal breast epithelium, 94 breast carcinomas and 24 benign and pre-malignant lesions of the mammary gland. All cases of normal breast epithelium and non-malignant lesions presented high levels of expression of class-I antigens. In contrast, 22 out of 94 carcinomas showed a reduction in the level of expression and a heterogeneous pattern. In addition, 31 tumors were considered negative for HLA-class-I expression, and 6 cases showed selective loss of HLA-ABC: 2 tumors for HLA locus A, and 4 for HLA locus B. We found a direct relationship between patient survival and HLA-negative phenotype (p less than 0.001), as well as between histological grade of malignancy and the level of expression of class-I antigens (p less than 0.0005). Moreover, the presence of class-I molecules was significantly related to tumor ploidy (p less than 0.005). Our results lead us to conclude that HLA-ABC-negative tumors have a higher metastatic potential and greater clinical aggressiveness: patients with carcinomas exhibiting low HLA expression have more lymph-node metastases (p less than 0.02) and achieve shorter survival times (p less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2066180     DOI: 10.1002/ijc.2910470726

Source DB:  PubMed          Journal:  Int J Cancer Suppl        ISSN: 0898-6924


  11 in total

1.  HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities.

Authors:  M Feinmesser; A Sulkes; S Morgenstern; J Sulkes; S Stern; E Okon
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

Review 2.  Targeting T cells with bispecific antibodies for cancer therapy.

Authors:  Lawrence G Lum; Archana Thakur
Journal:  BioDrugs       Date:  2011-12-01       Impact factor: 5.807

3.  Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma.

Authors:  Masanao Saio; Matt Teicher; Gaynor Campbell; Helen Feiner; Yara Delgado; Alan B Frey
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.

Authors:  María A Garrido; Teresa Rodriguez; Svitlana Zinchenko; Isabel Maleno; Francisco Ruiz-Cabello; Ángel Concha; Nicolás Olea; Federico Garrido; Natalia Aptsiauri
Journal:  Immunogenetics       Date:  2018-08-25       Impact factor: 2.846

5.  Upmodulation by estrogen of HLA class I expression in breast tumor cell lines.

Authors:  F Rodríguez; F Perán; F Garrido; F Ruiz-Cabello
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

6.  Expression of HLA-ABC, HLA-DR and intercellular adhesion molecule-1 in oesophageal carcinoma.

Authors:  J C Rockett; S J Darnton; J Crocker; H R Matthews; A G Morris
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

7.  Clinical implication of HLA class I expression in breast cancer.

Authors:  Koichi Kaneko; Sumiya Ishigami; Yuko Kijima; Yawara Funasako; Munetsugu Hirata; Hiroshi Okumura; Hiroyuki Shinchi; Chihaya Koriyama; Shinichi Ueno; Heiji Yoshinaka; Shoji Natsugoe
Journal:  BMC Cancer       Date:  2011-10-20       Impact factor: 4.430

8.  Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.

Authors:  Scott D Brown; Rene L Warren; Ewan A Gibb; Spencer D Martin; John J Spinelli; Brad H Nelson; Robert A Holt
Journal:  Genome Res       Date:  2014-04-29       Impact factor: 9.043

9.  Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours.

Authors:  F V Cromme; P F van Bommel; J M Walboomers; M P Gallee; P L Stern; P Kenemans; T J Helmerhorst; M J Stukart; C J Meijer
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

10.  Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.

Authors:  P Korkolopoulou; L Kaklamanis; F Pezzella; A L Harris; K C Gatter
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.